CMLPath to Care™
Extending The Max Foundation and Novartis collaboration for access to cancer therapies
CMLPath to Care™ is a unique global initiative that connects people living with chronic myeloid leukemia (CML) and their carers with effective treatments, professional medical capabilities, trained physicians and hands-on support. The initiative is directed by The Max Foundation with support from Novartis through drug donations and funding.
The origins of CMLPath to Care date back to 2002 when Glivec Internation Patient Assistance Program – a collaboration between Novartis Oncology and The Max Foundation – brought a never-before-seen level of care to thousands of people with CML. Since that time, GIPAP expanded to a global network of more than 75 low- and middle-income countries, over 450 treatment centers and more than 1400 trained physicians. Most importantly, it reached more than 75,000 patients in those countries. Since that time, the cancer care landscape has changed: there has been growth in healthcare infrastructures, an increase in the impact of patient groups, and the introduction of new and innovative therapies – all providing value to patients’ lives.
CMLPath to Care is an evolved compact between The Max Foundation and Novartis Oncology reflecting this new healthcare environment while continuing to support the one simple goal of both organizations – to enable people living with CML to be well.